

## Innovations in staging of prostate cancer

Poster Session 66

Monday, 27 March  
12:15 - 13:45

**Location:** Room London, North Hall (Level 1)

**Chairs:** N. Fossati, Milan (IT)  
M. Lardas, Nea Smirni-Athens (GR)  
J. Hugosson, Göteborg (SE)

### Aims and objectives of this session

This session will examine Innovations in prostate cancer staging, prognostic groups and lymph node identification.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

869

### 11C-choline versus 68Ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: Results from a large, multi-institutional salvage lymph node dissection series

**By:** Fossati N.<sup>1</sup>, Briganti A.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Suardi N.<sup>1</sup>, Colicchia M.<sup>2</sup>, Karnes J.<sup>2</sup>, Haidl F.<sup>3</sup>, Porres D.<sup>3</sup>, Pfister D.<sup>3</sup>, Heidenreich A.<sup>3</sup>, Herlemann A.<sup>4</sup>, Gratzke C.<sup>4</sup>, Stief C.<sup>4</sup>, Battaglia A.<sup>5</sup>, Everaerts W.<sup>5</sup>, Joniau S.<sup>5</sup>, Van Poppel H.<sup>5</sup>, Aksenov A.<sup>6</sup>, Osmonov D.K.<sup>6</sup>, Jünemann K.P.<sup>6</sup>, Abreu A.D.L.<sup>8</sup>, Almeida F.<sup>8</sup>, Fay C.<sup>7</sup>, Gill I.<sup>7</sup>, Mottrie A.M.<sup>9</sup>, Montorsi F.<sup>1</sup>

**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, <sup>3</sup>University of Cologne, Dept. of Urology, Cologne, Germany, <sup>4</sup>Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, <sup>5</sup>University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, <sup>6</sup>University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, <sup>7</sup>Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, <sup>8</sup>Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, <sup>9</sup>OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

870

### Introducing PSMA-Bone-PET-Index for quantitative assessment of osseous tumor burden in prostate cancer

**By:** Bieth M.<sup>2</sup>, Krönke M.<sup>2</sup>, Maurer T.<sup>1</sup>, Tauber R.<sup>1</sup>, Dahlbender M.<sup>1</sup>, Retz M.<sup>1</sup>, Gschwend J.<sup>1</sup>, Nekolla S.<sup>2</sup>, Menze B.<sup>2</sup>, Eiber M.<sup>2</sup>, Schwaiger M.<sup>2</sup>

**Institutes:**<sup>1</sup>Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, <sup>2</sup>Klinikum rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany

871

### Performance of 111In-PSMA-ligand radioguided surgery for identification of lymph node metastases: Correlation of tracer uptake and histopathology based on 310 single lymph nodes separated from lymphadenectomies in prostate cancer patients

**By:** Schaal K.<sup>1</sup>, Mix M.<sup>2</sup>, Stoykow C.<sup>2</sup>, Bartholomä M.<sup>2</sup>, Drendel V.<sup>3</sup>, Mäcke H.<sup>2</sup>, Gourni E.<sup>2</sup>, Wetterauer U.<sup>1</sup>, Schultze-Seemann W.<sup>1</sup>, Meyer P.T.<sup>2</sup>, Jilg C.A.<sup>1</sup>

**Institutes:**<sup>1</sup>Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, <sup>2</sup>Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Nuclear Medicine, Freiburg, Germany, <sup>3</sup>Medical Center, University of Freiburg, Faculty of Medicine, Institute for Pathology, Freiburg, Germany

872

### Prospective comparison of molecular and histopathologic detection of lymph node metastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: Prediction of biochemical recurrence

**By:** Heck M.<sup>1</sup>, Retz M.<sup>1</sup>, Bandur M.<sup>1</sup>, Souchay M.<sup>1</sup>, Vitzthum E.<sup>1</sup>, Weirich G.<sup>2</sup>, Schuster T.<sup>3</sup>, Autenrieth M.<sup>1</sup>, Kübler H.<sup>1</sup>, Maurer T.<sup>1</sup>, Thalgott M.<sup>1</sup>, Herkommer K.<sup>1</sup>, Gschwend J.<sup>1</sup>, Nawroth R.<sup>1</sup>

**Institutes:**<sup>1</sup>Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Urology, Munich, Germany, <sup>2</sup>Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Pathology, Munich, Germany, <sup>3</sup>McGill University, Dept. of Family Medicine, Montreal, Canada

873